FIELD: biotechnology.
SUBSTANCE group of inventions relates to biotechnology and immunology, in particular, to hinge structures in antigen-binding constructs. Proposed is an amino acid hinge region containing EPKSSDKTHTCPPCPPC. Also proposed is an amino acid hinge region containing the central hinge sequence CPPCPPC (SEQ ID NO: 52) or CPPCPPCPPC (SEQ ID NO: 54) attached to the upper hinge sequence ELKTPLGDTTHT (SEQ ID NO: 48) or EPKSSDKTHT (SEQ ID NO: 46). The above hinge regions are located in mini-antibodies binding to the target molecule. The mini-antibodies contained in the composition can be applied for diagnostic visualisation or delivery of a therapeutic payload.
EFFECT: inventions provide an improved construct of a mini-antibody containing the described hinge region, provide a possibility of improving the stability and/or reducing the aggregation of mini-antibodies, reducing the level of half-molecules to less than 1%.
25 cl, 80 dwg, 8 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES BINDING TO CD3 | 2013 |
|
RU2673153C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2752275C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| TRANSGENIC GENETIC LABELS AND METHODS OF USE | 2015 |
|
RU2822461C1 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
